Insilico Medicine collaborates with Asia Genomics to develop advanced personalized longevity suite

Insilico Medicine Inc, a big data analytics company located at the Emerging Technology Centers at the Johns Hopkins University at Eastern, announced an agreement with Asia Genomics, a Singapore-based rapidly growing molecular diagnostics company specializing in clinical genomics & genetic testing operating in major Asian countries including Vietnam, Malaysia and China.

"Asia Genomics is driven to transform healthcare in Asia through the power of genomics. The company is aggregating the most cutting-edge solutions in personalized healthcare from all over the world and establishing research partnerships in areas, where practical applications can be rapidly translated into clinical practice. We are very happy to collaborate with Insilico Medicine, one of the leaders in applying artificial intelligence to drug discovery and aging research. Ultimately, we bring the power of molecular biology technologies like genomics to Asia, enabling our partners and customers to better understand their health and longevity along with possible ways for intervention" said Dr Wong Mun Yew, Founder and CEO of Asia Genomics.

In the scope of the agreement, the companies will develop an advanced personalized longevity suite to identify individual aging related markers based on age-annotated genomic and transcriptomic data of individuals. In addition to aging biomarkers analysis, parties intend to develop artificially-intelligent age predicting algorithm implemented as an ensemble of multiple Deep Neural Networks (DNNs) trained and tested on Asian blood biochemistry samples.

"Asia Genomics is one of the leading molecular diagnostics and genomics company in Asia with state of the art equipment and highly qualified staff educated in top international universities. This company represents growing power of molecular biology technologies in Asia and is set to become the next Asian biotechnology unicorn. We are honoured to be selected as one of the providers of high-technology solutions for personalized longevity research," said Alex Zhavoronkov, CEO of Insilico Medicine. Inc.

Asia Genomics is developing a program for longevity science in Singapore with strategic expansion plans to different countries in Asia. It uses the genomic, transcriptomic, biochemistry and anonymized healthcare data to develop personalized health and longevity plans to maximize life potential.